Videos

An expert discusses how Friedreich ataxia is an autosomal recessive neurodegenerative disorder caused by trinucleotide (GAA) repeat expansion in the FXN gene, reducing frataxin protein production. This leads to mitochondrial dysfunction and progressive damage to the spinal cord, peripheral nerves, and heart. Patients present with progressive ataxia, dysarthria, sensory loss, and areflexia, typically manifesting between ages 5 and 15. Diagnosis relies on clinical assessment, genetic testing for GAA expansions, and supportive findings, including cardiomyopathy, scoliosis, and diabetes.

Experts discussed the negative health and societal effects of daylight saving time, advocating for a permanent switch to standard time to improve sleep, well-being, and productivity. [WATCH TIME: 6 minutes]

Experts discussed the biological misalignment caused by daylight saving time, emphasizing its negative effects on sleep, particularly in adolescents, and advocating for a shift to standard time to better align with natural circadian rhythms. [WATCH TIME: 6 minutes]

Neurology News Network. for the week ending March 15, 2025. [WATCH TIME: 3 minutes]

Experts discussed the effects of daylight saving time on sleep patterns, cognitive function, mood, and overall health, highlighting challenges and adaptation strategies. [WATCH TIME: 6 minutes]

An expert discusses the extended form of carbidopa/levodopa (Crexont) for managing OFF episodes, highlighting trial results that show decreased OFF time and increased ON time, as well as the use of subcutaneous loading of medications in Parkinson disease, which was well tolerated with skin issues as the main adverse effects and resulted in increased ON time without worsening dyskinesia.

An expert discusses how providers can accurately track episodes of OFF and dyskinesia, highlighting their impact on patients physically, socially, and psychologically, including the challenges dyskinesia poses for sleep and fine motor tasks.

Experts discussed how daylight saving time affects sleep patterns, particularly in individuals with insomnia and other sleep disorders, highlighting the challenges of adaptation and the risks of chronic sleep loss. [WATCH TIME: 5 minutes]

Kathleen Costello discusses her new role as interim CEO of the CMSC. She has the support of Jeff Wilken, CMSC president, and Tina Trott, CMSC director.

The interim chief executive officer at the Consortium of Multiple Sclerosis Centers invites healthcare professionals to the Consortium’s annual meeting from May 28–31 in Phoenix, Arizona. [WATCH TIME: 2 minutes]

The child neurologist and neuroimmunologist at Nationwide Children’s Hospital delved into the unique challenges and research objectives surrounding MOG antibody-associated disease. [WATCH TIME: 3 minutes]

The associate researcher at the University of California, San Francisco discussed a refined EAE model that could better replicate MS pathology, enabling deeper insights into demyelination, neuronal loss, and remyelination. [WATCH TIME: 6 minutes]

The professor of neurology and neurosurgery at McGill University discussed the evolving understanding of neuroimmune interactions in MS, highlighting how these interactions contribute to disease progression and potential repair mechanisms. [WATCH TIME: 4 minutes]

The assistant professor in the department of neurology at Mount Sinai talked about a recent study that highlighted how socioeconomic status and diet could significantly impact physical and cognitive outcomes in patients with MS. [WATCH TIME: 2 minutes]

Panelist discusses how treatment options for neurogenic bladder include pharmacological approaches such as anticholinergics, localized interventions such as botulinum toxin injections, and neuromodulation techniques (posterior tibial and sacral nerve stimulation). Surgery serves as a last resort when conservative treatments fail.

The professor of neurology at University of Colorado School of Medicine discussed the evolving landscape of MS treatment, highlighting the role of personalized medicine and biomarker-driven decision-making. [WATCH TIME: 5 minutes]

The instructor in the department of radiology at Weill Cornell Medicine discussed how structural and functional brain connectomes can potentially improve predictions of MS progression and treatment response. [WATCH TIME: 4 minutes]

Neurology News Network. for the week ending March 8, 2025. [WATCH TIME: 3 minutes]

The professor of neurosurgery and physiology at University of Colorado School of Medicine talked about how vagus nerve stimulation may promote remyelination and functional recovery in multiple sclerosis. [WATCH TIME: 4 minutes]

The child neurologist and neuroimmunologist at Nationwide Children’s Hospital provided clinical insight on the complexities of treating pediatric MOGAD, including treatment options, decision-making factors, and emerging therapies. [WATCH TIME: 4 minutes]

At the 2025 ACTRIMS Forum, the director of the MS Comprehensive Care Center at Stony Brook Medicine discussed the evolution of high-efficacy treatments for MS. [WATCH TIME: 4 minutes]

The assistant professor in the neurology department at the University of Utah in Salt Lake City discussed advancing personalized medicine for patients with neuromyelitis optica spectrum disorder, a rare disorder of the central nervous system. [WATCH TIME: 4 minutes]

The pediatric neurologist at Children’s Hospital of Philadelphia gave perspective on some of the main issues the clinical community is figuring out with gene therapies and their integration to clinical practice. [WATCH TIME: 3 minutes]

Panelist discusses how neurogenic bladder in neurological conditions manifests distinctly based on lesion location. Patients with multiple sclerosis typically experience detrusor overactivity and sphincter dyssynergia, leading to urgency and retention. Parkinson disease commonly presents with overactive bladder symptoms and nocturia due to impaired basal ganglia control. Cauda equina syndrome and lumbar disc herniation often result in detrusor areflexia and decreased sensation, causing retention and overflow incontinence.

At the 2025 ACTRIMS Forum, the system chief of neuroimmunology and multiple sclerosis at OhioHealth discussed the need for better tools to detect MS progression. [WATCH TIME: 3 minutes]

The director of the MS and Demyelinating Disease Center at Texas Tech University Health Sciences Center talked about early diagnosis, timely treatment, and minimizing therapy transition gaps to prevent severe disability in patients with NMOSD. [WATCH TIME: 4 minutes]

The assistant professor of neurology and neurosurgery at McGill University discussed the role of paramagnetic rim lesions as potential biomarkers of compartmentalized inflammation in MS. [WATCH TIME: 4 minutes]

The founder and executive director of the Sumaira Foundation talked about how the landscape of NMOSD treatment has drastically improved with FDA-approved therapies, while noting that accessibility and awareness remain significant challenges. [WATCH TIME: 4 minutes]

The assistant professor of medicine at the University of Toronto talked about emerging research on how prodromal symptoms may aid in the early identification of multiple sclerosis and neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]

At the 2025 ACTRIMS Forum, the assistant professor of neuroimmunology at McGill University talked about examining immune cell signatures to track disease worsening in multiple sclerosis. [WATCH TIME: 4 minutes]